Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CVX-096 · 1 trial · 1 indication
AUClast was defined as area under the concentration-time curve from time zero to the time of last measured concentration and calculated by using linear up/log down trapezoidal method.
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| CVX-096 | BIOLOGICAL | Subcutaneous administration of CVX-096 with doses ranging from 0.1 mg up to a maximum of 36 mg |
Inclusion Criteria: * Male and/or female patients (females will be women of non-childbearing potential) with an historical diagnosis of type 2 diabetes mellitus, who are currently being treated with metformin at a dose at or near maximum. * Hb A1c between 7-10%. * Fasting C-peptide \>0.4 nmol/L. E...
CVX-096 is an investigational monoclonal antibody being studied for the treatment of Type 2 Diabetes Mellitus. It is being developed by Pfizer, Inc. (NYSE: PFE) as a potential therapy for this metabolic condition.
CVX-096 is being developed by Pfizer, Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol PFE. The drug is an investigational monoclonal antibody in clinical development for Type 2 Diabetes Mellitus.
CVX-096 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The drug is being studied for its safety and pharmacokinetics in patients with Type 2 Diabetes Mellitus.
CVX-096 has one completed Phase 1 clinical trial, identified as NCT00886821, titled "A Safety and Pharmacokinetic Study of CVX-096 in Type 2 Diabetics." This trial enrolled 114 participants in the United States and was a randomized, double-blind study.
CVX-096 is not FDA approved. It is an investigational monoclonal antibody currently in Phase 1 clinical development for Type 2 Diabetes Mellitus. The drug has completed a Phase 1 safety and pharmacokinetic study but remains in clinical investigation.